Product Development and Innovation - In 2022, the company launched over 10 functional skincare products, enhancing its "big skin" product matrix[4] - The company achieved approval for 1 formulation product and 7 active pharmaceutical ingredients for overseas certification[2] - The company has expanded its product offerings, including the approval of linezolid glucose injection (100ml, 300ml), enhancing its portfolio in skin, tuberculosis, and anti-tumor medications[67] - The company has launched over 10 functional products in the skin care segment, including ceramide essence oil and acne gel, leveraging 30 years of clinical experience in dermatology[67] - The company is focusing on high-value raw materials and key intermediates through collaboration with domestic and international research institutions[145] - The company is actively pursuing new product registrations in the oncology and digestive system medication fields, enhancing its product pipeline[121] - The company aims to develop 3-5 new pharmaceutical products annually and ensure rapid approval of in-progress products[144] - The company is developing new products in the lithium-ion battery electrolyte sector, expanding its downstream industry chain[122] Financial Performance - The company's operating revenue for 2022 was approximately ¥13.23 billion, representing a 6.45% increase compared to ¥12.43 billion in 2021[42] - The net profit attributable to shareholders decreased by 35.12% to approximately ¥433.28 million from ¥670.05 million in the previous year[42] - The net profit after deducting non-recurring gains and losses was approximately ¥408.65 million, down 32.77% from ¥610.11 million in 2021[42] - The net cash flow from operating activities increased by 89.65% to approximately ¥2.41 billion, compared to ¥1.27 billion in 2021[42] - The company reported a total distributable profit of RMB 780,260,536.94 for the reporting period[194] - The company achieved a revenue share of 13.80% from overseas sales in its main business, primarily exporting to large multinational companies such as DuPont and Toray[79] - The company reported a significant asset impairment loss of ¥560.36 million, representing 34.53% of total profit, which is not expected to be sustainable[126] Market Expansion and Strategy - The company aims to strengthen its leading position in the prescription market and expand its market share in the outpatient retail sector[3] - The company is focusing on expanding its market presence in the dermatology sector, which is expected to grow significantly due to increasing health awareness among consumers[54] - The company is actively pursuing market expansion in the OTC sector while strengthening its position in the prescription market[61] - The company has covered over 200,000 terminal points in the outpatient market, actively expanding its marketing channels beyond hospitals[69] - The company has partnered with over 10 online platforms, including Alibaba Health and Meituan, to enhance its e-commerce presence[69] - The company plans to open 20 new chain clinics nationwide, increasing the total to 50 clinics[148] Operational Efficiency and Production Capacity - The company’s raw material drug production bases in Changshou and Hanjing were officially put into operation, enhancing production capacity[7] - The company has established four major formulation production bases and three major raw material production bases, enhancing its supply chain stability and production efficiency[68] - The company invested over 3 billion RMB in production capacity expansion and digital transformation since 2015, significantly increasing production capabilities by 4-8 times at its main production bases[68] - The company is focusing on enhancing production efficiency to improve product competitiveness in the agricultural chemicals sector[57] - The company is committed to smart and green manufacturing to enhance product quality and expand production capacity[77] Research and Development - The company has a strong R&D team and core technologies in the production and purification of chlorosulfonic acid and acyl chloride products, ensuring a competitive edge[80] - The company has established a strong R&D infrastructure with four major centers and nearly 400 R&D personnel, supporting its drug development initiatives[94] - The company has a total of 45 authorized patents in the new materials sector, with 14 being invention patents, showcasing strong R&D capabilities[87] - R&D personnel increased by 8.10% to 1,281 in 2022, with the proportion of R&D staff rising to 10.08% of total employees[122] - The company is focusing on green and clean technology innovations in its production processes to enhance core competitiveness[121] Medical Services and Healthcare - The Beijing Huasheng Rehabilitation Hospital was approved for medical insurance qualifications, becoming a designated medical institution in Beijing[11] - The Chongqing Songshan Hospital served over 1.5 million patients, with the addition of 23 specialty outpatient clinics[10] - The company’s medical services are expected to continue growing, with a focus on innovative healthcare business models[9] - The company has established a comprehensive medical system that enhances collaboration among medical institutions, leveraging advanced technologies from the Swiss Basel Biotherapy Center to improve healthcare quality[98] Sustainability and Environmental Impact - The company has been recognized as a national "green factory" in the pharmaceutical industry, enhancing its sustainability credentials[7] - The company is committed to sustainable development and aims to become a comprehensive provider of agricultural chemical products globally[150] - The company has implemented a circular economy approach by utilizing sulfur dioxide separation and recycling, reducing production costs and environmental impact[103] - The company is addressing environmental policy risks by investing in environmental technology and establishing a risk-oriented internal management system[152] Governance and Compliance - The company adheres to legal and regulatory requirements for corporate governance, ensuring transparency and protection of investor rights[164] - The board of directors consists of 6 members, including 2 independent directors, ensuring compliance with governance standards[165] - The company has established specialized committees, including a strategy committee and an audit committee, to enhance decision-making processes[166] - The internal audit department operates independently and reports to the audit committee, ensuring effective internal control implementation[197] Tourism Business - The company operates three cable cars in the Yulong Snow Mountain Scenic Area and three in the Taibai Mountain National Forest Park, being the sole operator in these areas[83] - The company has a diverse tourism business model that includes cable car transport, scenic area transportation, hotel operations, and tourism performances[83] - The tourism service segment generated revenue of CNY 438,785,148.54, down 14.59% from the previous year[109] - The company faces intensified competition in the tourism market, particularly in the mid-to-high-end hotel sector due to the influx of international hotel brands[159]

公司董事会及管理层衷心感谢广大投资者对公司的关注与支持，欢迎广大投 资者积极参与。 华邦生命健康股份有限公司 董 事 会 证券代码：002004 证券简称：华邦健康 公告编号：2023013 华邦生命健康股份有限公司 关于召开 2022 年度业绩网上说明会的公告 （问题征集专题页面二维码） 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日在 公司指定信息披露网站巨潮资讯网（www.cninfo.com.cn）披露了公司《2022 年年 度报告》及其摘要。为使广大投资者进一步了解公司经营情况，公司拟于 2023 年 5 月 5 日（星期五）下午 15:00-17:00 在全景网举行 2022 年度业绩说明会，本 次说明会将采用网络远程方式举行，投资者可登陆"全景•路演天下" （http://rs.p5w.net）参与本次年度业绩说明会。出席本次年度业绩说明会的人员 有：公司董事、总经理张海安先生，董事、董事会秘书彭云辉女士，独立董事黎 明先生，财务总监王剑先生。 为充分尊重投资者、提 ...

证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|---------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 西南证券，天弘基金，厚石资本，广发资管，前海旗隆，交 | | 人员姓名 | | 银施罗德，敦和资产，天马资产，之上资产，成都数源量 | | | 金，石运投资 | 化，太武投资，和君投资，财富证券，兴证资管，金信基 | | | | | | 时间 | 2015 年 9 月 11 ...

证券代码：002004 证券简称：华邦健康 | --- | --- | --- | |-----------------------|------------------------|-----------------------------------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ | 新闻发布会 □路演活动 | | | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 民生证券，西部证券，方正证券，华泰证券，万家基金，鹏 | | 人员姓名 | | 华基金，静山资管，法国巴黎银行，宏道投资，化医新天投 | | | | 资。 | | 时间 | 2016 年 1 月 6 | 日 | | 地点 | 公司会议室 | | | | | | | 上市公司接待人 员姓名 | | 董事、董事会秘书彭云辉女士，投资运营部部长张一卓先 生，综合管理科科长胡菁菁女士。 | | ...

证券代码：002004 证券简称：华邦健康 | --- | --- | --- | |-----------------------|-------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ | 新闻发布会 □路演活动 | | | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 西南证券、中投证券、君利信合、文储投资、明泰资产、渤 | | 人员姓名 | 海汇金、新皖投资 | | | 时间 | 2016 年 9 月 13 | 日 | | 地点 | 公司会议室 | | | 上市公司接待人 员姓名 | | 董事、董事会秘书彭云辉女士、证券事务代表陈志先生。 | | | 公司于 2016 | 年 9 月 13 日在公司会议室举办投资者调研 | | 投资者关系活动 | | 活动，就公司的经营状况、医疗产业布局情况等投资者关心 ...